GlassScriptPhysician profile
Mark Allen Henderson
NPI 1841370707
$756.74
in general payments reported to CMS, 2019-2025
23 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $82.96 · 2021: $24.40 · 2022: $99.59 · 2023: $20.51 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $188.93 | 2019 | |
| Genentech USA, INC. | $113.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $46.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $37.79 | 2019-2025 | |
| Eisai INC. | $34.32 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.48 | 2025 | Keytruda, Keytruda Qlex |
| Adaptive Biotechnologies Corporation | $27.20 | 2025 | Clonoseq |
| E.R. Squibb & Sons, L.L.C. | $24.40 | 2021 | |
| Janssen Biotech, INC. | $23.49 | 2019-2020 | |
| Becton, Dickinson and Company | $23.06 | 2025 | Allpoints |
| Clovis Oncology, INC. | $22.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.58 | 2019 | |
| Siemens Medical Solutions USA, INC. | $20.51 | 2023 | Aria Radiation Therapy Management Software, Truebeam |
| Takeda Pharmaceuticals U.S.A., INC. | $18.57 | 2019 | |
| Beone Medicines USA, INC. | $18.07 | 2025 | Brukinsa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $18.05 | 2019 | |
| Daiichi Sankyo INC. | $15.35 | 2019 | |
| Lilly USA, LLC | $14.51 | 2019 | |
| Karyopharm Therapeutics INC. | $12.86 | 2020 | |
| Coherus Oncology, INC. | $12.80 | 2020 | |
| Amgen INC. | $12.67 | 2019 | |
| Foundation Medicine, INC. | $11.76 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.